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There is an urgent need for health policymakers to pay attention to recent developments in gene therapy for sickle cell disease (SCD), a treatment approach directed principally at treating the cause rather than the symptoms of genetic diseases
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. Sickle cell anaemia (SCA), one of the variants of SCD, is an inherited disease in which mutated red blood cells are curved into sickle (crescent) shapes, resulting in poor oxygenation of cells. It occurs globally, with more than 230 000 infants born with the condition in Africa annually
Patients with SCA suffer from recurrent anaemia, infections, tissue damage, strokes, excruciating pain and fatal organ failures, with vaso-occlusive crises being the hallmark of its acute presentation. Sadly, 50-80% of infants born with the disease die before the age of 5 years in Africa
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. The financial impact is devastating, especially for rural households in SubSaharan Africa -where 60% of the population live -with very limited access to even routine health care 3, 4 .
Early diagnosis through newborn screening, prophylactic therapy, and comprehensive care programs including hydroxyurea therapy as well as bone marrow therapy, are current treatment options, in well-resourced countries. Bone marrow transplant offers a promising prospect for cure 5 ; however, this line of treatment is limited because it carries significant risks, including infections, graft rejection and up to a 10% chance of mortality 6 . Moreover, human leucocyte antigen matching and other associated costs (pre-, peri-and post-treatment) are often outside the reach of many urban, let alone rural, families affected or afflicted by the disease.
Currently, several innovative approaches are at different stages of trials. These include:
• gene addition, whereby a new haemoglobin gene is inserted into the cells' DNA using a viral vector with the old, faulty haemoglobin gene still being present (the latter goes silent as the new gene takes over)
• gene editing, which corrects sickle cell genes with tools such as nucleases and others including zinc finger nuclease, transcription activator-like effector nuclease and clustered regularly interspaced short palindromic repeats
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• disabling of the BCL11A gene, which causes the switch from foetal to adult haemoglobin, so that patients can continue to produce foetal haemoglobin instead of the mutated adult variant
Although some challenges remain, including how to minimise off-target or unwanted injurious effects and ensuring that the edited/new stem cells survive and generate healthy red blood cells after they are reinserted into the bone marrow, considerable improvements have been made 8 .
